About HemoSense
HemoSense is a Healthcare company based in San Jose (United States) founded in 1997, and was acquired by Abbott in November 2007. Rapid Point-of-Care Coagulation analyzer. HemoSense has raised $17.7 million across 2 funding rounds from investors including Tredegar, Abbott Global Point of Care and NEA. The company was acqui-hired. Its focus areas include Life Sciences, Hematology, In Vitro Diagnostics Tests and Coagulopathies. Its competitors include Hemosonics, Stasys and Exactus; 2 of its 3 listed competitors have raised funding.
Company details
HemoSense was founded in 1997 in San Jose, United States, and focused on the medical device sector. Development, manufacturing, and marketing of handheld systems for monitoring blood coagulation in warfarin patients were conducted. The INRatio System was provided to measure clotting time at the point of care. Acquisition by Alere Diagnostics occurred in 2013.
- Headquarters San Jose, United States
- Stage Public
- SectorsHealthcare
- Phone•••• ••••
- Website hemosense.com
- Social LinkedIn
- Acquired by Abbott (Nov 2007)
Funding Insights of HemoSense
HemoSense has successfully raised a total of $17.7M across 2 strategic funding rounds. The most recent funding activity was a Post-IPO round of $7 million completed in December 2006. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $17.7M
- Total Rounds 2
- Last Round Post-IPO — $7M
- First Round $17.7M
(Oct 2000)
- Investors Count 3
All 2 funding rounds of HemoSense with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2006 | $7M | Post-IPO | – | – | |
| Oct 2000 | $17.7M | Series C | – | – |
4 investors in total: 4 institutional.
Investors in HemoSense
HemoSense has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Tredegar, Abbott Global Point of Care and NEA.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
Invests in biotech firms developing life-saving drugs and technologies. | mpmcapital.com | |||
Plastic films and aluminum products are manufactured by Tredegar. | 1988 | tredegar.com | Chesterfield, United States | |
Rapid diagnostics products and solutions for point-of-care testing are provided. | 1900 | globalpointofcare.abbott | Waukegan, United States |
Investor details for HemoSense
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of HemoSense
5 dated milestones of HemoSense across 10 years, from founding to its latest funding, stage changes and deals.
- Founded HemoSense is founded.
- Funding First funding round of $17.7M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $7.0M.
- Exit Acquired by Abbott.
Competitors of HemoSense
HemoSense has 3 listed competitors in our database, 2 of them funded. They include Hemosonics, Stasys and Exactus.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| hemosonics.com | 2004 | Charlottesville, United States | $24.92M | IVD for hemostasis characterization | ||
| stasysmedical.com | 2013 | Seattle, United States | $2.85M | Provider of POC device for analyzing blood clotting disorders and platelet dysfunction | ||
| exactusinc.com | 2008 | Glen Allen, United States | 3 | POC diagnostics for fibrinolytic status assessment are developed. |
Detailed competitors of HemoSense
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Hematology
3 companies that operate in the same segment as HemoSense (Hematology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Catheter-based thrombectomy devices for vascular emboli removal are developed. | 2011 | Irvine, California, United States | USD 51.89 M | USD 493.63 M | 696 | |
Small molecules are developed to treat hematologic and musculoskeletal disorders. | 2016 | Lexington, Kentucky, United States | USD 90 M | USD 244.06 M | 169 | |
Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders | 2016 | Menlo Park, California, United States | USD 300 M | 384 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about HemoSense
HemoSense was founded in 1997 and raised its 1st funding round 3 years after it was founded.
HemoSense is headquartered in San Jose, United States. It is registered at San Jose, California, United States.
HemoSense is a funded company, having raised a total of $17.7M across 2 funding rounds to date. The company's 1st funding round was a Series C of $17.7M, raised on Oct 2000.
HemoSense was founded in 1997 in San Jose, United States, and focused on the medical device sector. Development, manufacturing, and marketing of handheld systems for monitoring blood coagulation in warfarin patients were conducted. The INRatio System was provided to measure clotting time at the point of care. Acquisition by Alere Diagnostics occurred in 2013.
HemoSense's top competitors include Hemosonics, Stasys and Exactus.
HemoSense has 4 investors. Key investors include Tredegar, Abbott Global Point of Care, NEA, and Turmeric Acquisition Corp.
Yes. HemoSense was acquired by Abbott in November 2007.